Image via WikipediaThere may be dialogue concerning these meds, given a report/study published in a gastroenterology journal. The journal article is titled: Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies.
The study noted that Glucagon-like peptide-1−based therapy is gaining widespread use for type 2 diabetes, although there are concerns about risks for pancreatitis and pancreatic and thyroid cancers. There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, given their effects on immune function.
The article's conclusion: That case reports and animal studies indicating an increased risk for pancreatitis with glucagon-like peptide-1−based therapy. The findings also raise caution about the potential long-term actions of these drugs to promote pancreatic cancer.
Read the full article here: http://www.gastrojournal.org/article/S0016-5085(11)00172-7/fulltext